Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQ: RYTM · Real-Time Price · USD
104.52
-0.22 (-0.21%)
Sep 2, 2026, 10:52 AM EDT - Market open
Rhythm Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 17 analysts polled by S&P Global, Rhythm Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $140.19. The average 1-year stock price forecast is 34.13% higher than the current stock price, while the lowest is $105 (+0.46%) and the highest is $160 (+53.08%).
Price Target: $140.19 (+34.13%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Rhythm Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 11 | 11 | 11 | 10 | 10 |
| Buy | 4 | 4 | 4 | 4 | 5 | 5 |
| Hold | 1 | 1 | 1 | 1 | 1 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 16 | 16 | 16 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Deutsche Bank | Deutsche Bank | Hold Initiates $120 | Hold | Initiates | $120 | +14.81% | Aug 28, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Reiterates $150 | Buy | Reiterates | $150 | +43.51% | Aug 25, 2026 |
| Guggenheim | Guggenheim | Buy Reiterates $143 | Buy | Reiterates | $143 | +36.82% | Aug 25, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Reiterates $146 | Buy | Reiterates | $146 | +39.69% | Aug 10, 2026 |
| RBC Capital | RBC Capital | Buy Reiterates $141 → $155 | Buy | Reiterates | $141 → $155 | +48.30% | Aug 5, 2026 |
Financial Forecast
Revenue This Year
313.73M
from 189.76M
Increased by 65.33%
Revenue Next Year
560.25M
from 313.73M
Increased by 78.57%
EPS This Year
-3.07
from -3.11
EPS Next Year
-0.61
from -3.07
EPS and Forward PE are based on non-GAAP adjusted numbers.